Portfolio

TolerogenixX

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.

Info & Contact

Dr. Matthias Schaier
Phone:
+49 6221 5639930
Web:
www.tolerogenixx.com

Address

TolerogenixX GmbH
Im Neuenheimer Feld 162
69120 Heidelberg

In portfolio

21. Dec 2016